

SUPPLEMENTARY TABLE 1 The characteristics of patients in SLE group and control group

Characteristics	SLE group (n = 352)	Control group (n = 385)	P
Sex female	322 (91.5%)	279 (72.5%)	< 0.001
Age (years), median (range)	36.0 (13.0–81.0)	55.0 (16.0–83.0)	< 0.001
<40	204 (58.0%)	88 (22.9%)	< 0.001
≥40	148 (42.0%)	297 (77.1%)	< 0.001
Disease duration (years), median (range)	6.4 (0.0–37.0)		
≤1	84 (23.9%)		
1–≤3	22 (6.3%)		
3–≤5	38 (10.8%)		
>5	208 (59.1%)		

Except where indicated otherwise, values are n (%). SLE: systemic lupus erythematosus.

SUPPLEMENTARY TABLE 2 The comparison of SLERPI items for patients with SLERPI >7 and ≤7 in the control group

	SLERPI >7 (n = 41)	SLERPI ≤7 (n = 344)	P
Malar rash or maculopapular rash	7 (17.1)	5 (1.5)	< 0.001
Subacute cutaneous lupus erythematosus or discoid lupus erythematosus	0 (0)	1 (0.3)	1.000
Alopecia	7 (17.1)	7 (2.0)	< 0.001
Mucosal ulcers	2 (4.9)	20 (5.8)	1.000
Arthritis	18 (43.9)	106 (30.8)	0.09
Serositis	4 (9.8)	5 (1.5)	0.009
Leucopenia <4000/μl (at least once)	21 (51.2)	82 (23.8)	< 0.001
Thrombocytopenia or autoimmune haemolytic anaemia	23 (56.1)	14 (4.1)	< 0.001
Neurological disorder	0 (0)	0 (0)	NA
Proteinuria >500mg/24 hours	7 (17.1)	2 (0.6)	< 0.001
ANA	40 (97.6)	146 (42.4)	< 0.001
Low C3 and C4	8 (19.5)	24 (7.0)	0.014
Immunological disorder (any of: anti-DNA, anti-Sm, anti-phospholipid antibodies)	9 (22.0)	11 (3.2)	< 0.001
Interstitial lung disease	6 (14.6)	47 (13.7)	0.865

Values are n (%). ANA: antinuclear antibody; C3: complement 3; C4: complement 4; NA: not applicable; SLERPI: systemic lupus erythematosus risk probability index.